Total Price: $0.00
Contact Information
Recombinant Human GLα protein (His tag)
SKU: PDEH100177-100
To better serve you, we would like to discuss your specific requirement.
Please Contact Us for a quote.
Recombinant Human GLα protein (His tag)
| SKU # | PDEH100177 |
| Expression Host | E. coli |
Description
| Synonyms | Alpha-Galactosidase A;Alpha-D-Galactosidase A;Alpha-D-Galactoside;Galactohydrolase;Melibiase;Agalsidase;GLA;GLAL |
| Species | Human |
| Expression_host | E.coli |
| Sequence | Leu 32-Leu 429 |
| Accession | P06280 |
| Mol_Mass | 43.7 kDa |
| AP_Mol_Mass | 48 kDa |
| Tag | N-His |
| Bio_Activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin level | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis |
Background
α-Galactosidase A is a homodimeric glycoprotein that belongs to the glycosyl hydrolase 27 family. It is a lysosomal enzyme and used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. α-Galactosidase A can hydrolyze terminal α-galactosyl moieties from glycolipids and glycoproteins and catalyze the hydrolysis of melibiose into galactose and glucose. Defects α-Galactosidase A are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease with glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease.